Quarterly report pursuant to Section 13 or 15(d)

Statement of Operations

v2.4.0.6
Statement of Operations (USD $)
 3 Months Ended 6 Months Ended 135 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Revenues:          
Research $ 0 $ 0 $ 0 $ 0 $ 0
Expenses:          
General and administrative 742,594 927,617 1,470,766 2,036,790 28,817,761
Research and development 1,018,256 5,417,094 2,060,956 8,134,622 33,946,559
Patent fees 77,373 103,225 179,962 175,739 2,280,967
Depreciation and amortization 10,721 10,650 21,442 24,777 661,979
Total Expenses 1,848,944 6,458,586 3,733,126 10,371,928 65,707,266
Loss from Operations (1,848,944) (6,458,586) (3,733,126) (10,371,928) (65,707,266)
Other Income (Expense)          
Realized loss on marketable securities   (3,960) 0 (3,960) (13,301)
Interest income 4,294 38,849 10,543 81,322 1,431,850
Interest expense         (301,147)
Other income         56,047
Unrealized loss gain on fair value of warrants 802,248 594,845 540,387 127,220 4,216,492
Unrealized gain on fair value of put feature on common stock         2,315,539
Financing expense       (97,667) (640,023)
Beneficial conversion feature         (1,625,000)
Total Other Income (Expense) 806,542 629,734 550,930 106,915 5,440,457
Net Loss Before Provision for Income Taxes (1,042,402) (5,828,852) (3,182,196) (10,265,013) (60,266,809)
Provision for Income Taxes 0 0 0 0 0
Net Loss $ (1,042,402) $ (5,828,852) $ (3,182,196) $ (10,265,013) $ (60,266,809)
Loss per share, basic and diluted $ (0.01) $ (0.06) $ (0.03) $ (0.11)  
Weighted average number of shares outstanding, basic and diluted 95,345,656 95,237,656 95,345,656 90,769,492